Hopman Mark 4

What Happened

• Mark Hopman, Chief Commercial Officer of Beta Bionics (BBNX), reported a sale of 5,329 shares on June 2, 2026. The reported transaction value was approximately $67,183 (5,329 shares × reported price ~$12.61). The Form 4 lists the transaction as an open-market or private sale (code S).

Key Details

• Transaction date: 2026-06-02; Filing date: 2026-06-03 (filed next day).
• Price and amounts: 5,329 shares disposed; reported price per share $12.61. Footnote reports weighted average sale price $12.6071 and a price range of $12.30–$12.93; full per-price breakdown available upon request (per issuer/SEC staff).
• Reason: Footnote states shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Shares owned after transaction: Not disclosed in this Form 4.
• Timeliness: Filing appears timely (filed the business day after the transaction); no late-filing flag noted.

Context

• This was a sell-to-cover tied to RSU vesting (a routine withholding transaction) rather than an independent open-market sell intended to change the holder’s net position. Such tax-withholding sales are common and do not, by themselves, necessarily indicate the insider’s view on the company’s prospects.